STOCK TITAN

How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Kiora Pharmaceuticals (KPRX) posted an on-demand video in which CEO Brian M. Strem discusses the in-licensing of KIO-401 (mitucapistat). The investigational oral drug is being developed for sudden vision loss caused by central retinal artery occlusion (CRAO). It has been evaluated in Phase 2 and Phase 3 CRAO studies in Japan.

Kiora plans to start a multinational Phase 3 CRAO trial in 2027 to support a regulatory application. It also plans a Phase 2b trial in non-arteritic anterior ischemic optic neuropathy (NAION). The video will be available for 90 days in the Events section of Kiora’s investor relations website.

Loading...
Loading translation...
3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Multinational Phase 3 CRAO trial of KIO-401 is planned to start in 2027
  • Minor point. Forward-looking: it has not happened yet and may not happen.Phase 2b NAION trial is planned to evaluate KIO-401 in a second condition
  • Minor pointPhase 2 and Phase 3 CRAO studies have already evaluated KIO-401 in Japan

Negative

  • None.

Key Figures

Completed CRAO study stages: Phase 2 and Phase 3 Planned CRAO registration trial: Phase 3 in 2027 Planned NAION trial: Phase 2b
Completed CRAO study stages
Phase 2 and Phase 3
KIO-401 studies in Japan
Planned CRAO registration trial
Phase 3 in 2027
Multinational; planned initiation
Planned NAION trial
Phase 2b
KIO-401; planned evaluation

Historical Context

1 past event · Latest: Oct 29
1 event
  1. Oct 29

    KIO-401 license

    24h Move
    -25.4%

    Senju licensed KIO-401 outside Asia; Japanese Phase 2/3 studies, multinational Phase 3 targeted for 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

naion
1 terms
naion medical
"non-arteritic anterior ischemic optic neuropathy (NAION)."
Nonarteritic anterior ischemic optic neuropathy (NAION) is a sudden loss of vision caused by reduced blood flow (ischemia) to the front portion of the optic nerve. It typically produces painless, often partial vision loss in one eye on awakening or over hours to days and is linked to risk factors that affect small blood vessels, such as high blood pressure, diabetes, sleep apnea, and an anatomically crowded optic nerve head; it is distinct from arteritic AION, which is caused by inflammatory artery disease.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

San Diego, California--(Newsfile Corp. - November 19, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has posted an on-demand video featuring President and CEO Brian M. Strem, Ph.D., discussing the in-licensing of KIO-401 (mitucapistat), an investigational oral calpain inhibitor for sudden vision loss caused by central retinal artery occlusion (CRAO). Click here or on the following image to view the video.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/8481/324751_b944217f14af99c3_001.jpg

Cannot view this video? Visit: 

https://d1io3yog0oux5.cloudfront.net/_4b761e6c9445bbf9c0fa832060f4ff8d/kiorapharma/files/Brian_Strem_Interview_Audiogram_re_KIO-401_with_FWS.mp4

KIO-401 has been evaluated in Phase 2 and Phase 3 CRAO studies in Japan. Building on those studies, Kiora plans to initiate a multinational Phase 3 registration trial in CRAO in 2027. The company also plans to evaluate KIO-401 in a Phase 2b trial in non-arteritic anterior ischemic optic neuropathy (NAION).

The video interview will be available for 90 days in the Events section of Kiora’s investor relations website.

About Kiora

Kiora Pharmaceuticals is a late-stage retinal therapeutics company developing small-molecule therapies targeting differentiated biological pathways implicated in vision-threatening diseases.

KIO-401 is an oral, neuroprotective calpain inhibitor in development for central retinal artery occlusion (CRAO) and non-arteritic anterior ischemic optic neuropathy (NAION), two rare, acute ischemic ophthalmic diseases with no approved pharmacologic treatments. Kiora is planning a multinational Phase 3 registration trial in CRAO and a Phase 2b clinical trial in NAION. The KIO-401 platform also has potential applications in additional ophthalmic indications, including glaucoma, where calpain-mediated injury may contribute to disease progression.

KIO-301 is a partnered Phase 2 photoswitch therapy for advanced retinitis pigmentosa. KIO-104, a DHODH inhibitor previously evaluated in the KLARITY clinical trial for retinal inflammation and fibrosis, is available for partnering or out-licensing.

For more information, visit www.kiorapharma.com.

Forward-Looking Statements

This update contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Kiora's plans for KIO-401, the targeted 2027 start of a multinational Phase 3 registration trial in CRAO and the planned Phase 2b trial in NAION.

These statements reflect management's current expectations. Actual results could differ materially due to risks and uncertainties, including whether findings from prior studies in Japan can be replicated, whether regulatory feedback changes trial design or timing, the cost and feasibility of enrolling and conducting the trials, and Kiora's ability to raise sufficient capital to fund development. Additional risks are described under "Risk Factors" in Kiora's Annual Report on Form 10-K, filed March 25, 2026, and in subsequent SEC filings.

These statements speak as of the date of this update. Kiora disclaims any obligation to update them in light of later events or new information, except as required by law.

Contacts

Investors
Investors@kiorapharma.com

Media

Susan Sharpe
Linnden Communications
susan@linndencom.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324751

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What clinical trials does Kiora Pharmaceuticals plan for KIO-401?

Kiora plans a multinational Phase 3 CRAO trial starting in 2027 and a Phase 2b NAION trial. The Phase 3 trial is intended to support a regulatory application and builds on prior CRAO studies in Japan.

Keep reading